
Xeris Biopharma Holdings, Inc.: updates and filings
Price
$16.97
November 20, 2026Market cap $3.1B
What Ploutos Investor adds for Xeris Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 30% since Nov 5, 2026, when the 10-Q these figures come from was filed ($13.08 then, $16.97 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Nov 2, 2026Officer or director change, Regulation FD disclosureForm8-K
- Oct 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 14, 2026Other material eventsForm8-K
- Sep 9, 2026Regulation FD disclosureForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 17, 2026Unregistered sale of shares, other material eventsForm8-K
- Jun 30, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jun 11, 2026Unregistered sale of shares, other material eventsForm8-K
- Jun 5, 2026Shareholder voteForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Apr 21, 2026Officer or director changeForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 2, 2026Shares registered for employeesFormS-8
- Mar 2, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 2, 2026Results of operationsForm8-K
- Feb 27, 2026Regulation FD disclosureForm8-K
- Jan 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Nov 2, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Oct 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 14, 2026 | 8-K | Other material events | Document |
| Sep 9, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 17, 2026 | 8-K | Unregistered sale of shares, other material events | Document |
| Jun 30, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jun 11, 2026 | 8-K | Unregistered sale of shares, other material events | Document |
| Jun 5, 2026 | 8-K | Shareholder vote | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 21, 2026 | 8-K | Officer or director change | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 2, 2026 | S-8 | Shares registered for employees | Document |
| Mar 2, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 2, 2026 | 8-K | Results of operations | Document |
| Feb 27, 2026 | 8-K | Regulation FD disclosure | Document |
| Jan 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 2, 2021.
The full analysis
What do Xeris Biopharma's filings show?
The filings are where every one of Xeris Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.